ilaprazole has been researched along with gastrins in 2 studies
| Studies (ilaprazole) | Trials (ilaprazole) | Recent Studies (post-2010) (ilaprazole) | Studies (gastrins) | Trials (gastrins) | Recent Studies (post-2010) (gastrins) |
|---|---|---|---|---|---|
| 53 | 24 | 42 | 12,748 | 659 | 786 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, DY; Cho, H; Cho, M; Choi, MK; Jeong, HE; Kim, DY; Lee, JY; Shin, JG; Shin, JS; Shon, JH; Yeo, CW | 1 |
| Cho, KH; Kim, DY; Kukulka, M; Lee, JY; Park, HL; Park, SH; Shin, JS; Wu, JT | 1 |
2 trial(s) available for ilaprazole and gastrins
| Article | Year |
|---|---|
Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Benzimidazoles; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Gastrins; Genotype; Humans; Hydrogen-Ion Concentration; Male; Polymorphism, Genetic; Proton Pump Inhibitors; Republic of Korea; Sulfones; Sulfoxides; Time Factors | 2012 |
The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Esomeprazole; Female; Gastrins; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Proton Pump Inhibitors | 2014 |